NDATOPICALSOLUTION
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
ESKATA (hydrogen peroxide) by Aclaris Therapeutics is 12. First approved in 2017.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ESKATA is a topical hydrogen peroxide solution approved by the FDA in December 2017 for the treatment of seborrheic keratosis, a common benign skin growth. The mechanism of action remains unknown, but hydrogen peroxide rapidly dissociates into water and reactive oxygen species upon application with no systemic absorption demonstrated. This niche dermatology product represents a unique chemical approach to a cosmetic-medical indication.
Peak8.8 years to LOE
ESKATA is in peak commercial phase with minimal competitive pressure, suggesting a stable but specialized market with limited team expansion opportunities.
Mechanism of Action
12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action for ESKATA for the treatment of seborrheic keratosis is unknown. 12.2 Pharmacodynamics The pharmacodynamics of ESKATA in the treatment of seborrheic keratosis are unknown. 12.3 Pharmacokinetics Following application of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response
Started Jan 2017
12 enrolled
Breast Cancer
Subjective Comfort With Multipurpose and Hydrogen Peroxide Lens Care Solutions in Soft Contact Lens Wearers
Started Jun 2010
78 enrolled
Contact Lens Wear
Why This Matters for Your Career
Worked on ESKATA at Aclaris Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.